Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $38.90 Analyst target: $52.62 Upside: 35.27%
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The company is headquartered in Boulder, Colorado.
See the full interactive analysis & chart →Informational only — not investment advice.